Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol

Fig. 1

Predictive factors of Week 12 response in CZP-treated patients.

Randomised set (NRI). Patients received CZP 200 mg Q2W (400 mg loading dose at Weeks 0, 2 and 4) plus non-biologic background medication. aIncluded in the predictive model as continuous variables; for these factors, an odds ratio >1 indicates a higher probability of larger values being predictive of a response. ASAS40 Assessment of SpondyloArthritis International Society 40%, ASDAS Ankylosing Spondylitis Disease Activity Score, ASDAS-ID ASDAS inactive disease (ASDAS <1.3), ASDAS-MI ASDAS major improvement (reduction in ASDAS ≥2.0), BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50%, CI confidence interval, CRP C-reactive protein, CZP certolizumab pegol, NRI non-responder imputation, PtGADA Patient’s Global Assessment of Disease Activity, Q2W every 2 Weeks, ULN upper limit of normal (9.99 mg/L), vs versus

Back to article page